Catalyst Calendar
Scope

Mon, Jun 1, 2026

1 updates
IMTX
8:00 AM

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanoma Anzu-cel showed a 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and

Presentation / Abstract • Phase 1ASCO oral presentation Mon, Jun 1, 2026immatics.com

Sun, May 31, 2026

1 updates
IMTX
9:00 AM

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a

Presentation / Abstract • Phase 1Oral presentation Sun, May 31, 2026, 8:00 AM CDTimmatics.com

Sat, May 30, 2026

1 updates
IMTX
8:00 AM

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete

Presentation / Abstract • Phase 1ASCO oral presentation Sat, May 30, 2026, 8:00 AM CDTimmatics.com

Tue, May 12, 2026

1 updates
IMTX
7:00 AM

Immatics Announces First Quarter 2026 Financial Results and Business Update

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027 Multiple key clinical data sets expected in 2026 across the portfolio, including four clinical-stage cell therapy and

Presentation / Abstract • Phase 1ASCO abstract release Fri, May 29, 2026immatics.com

Tue, Apr 21, 2026

1 updates

Fri, Apr 17, 2026

1 updates